文献速递贫血与红细胞疾病

铁转运蛋白抑制剂减轻缺氧镰状细胞病小鼠肺动脉高压

Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice.
PubMed 文献 · Blood Adv · 2026-01-01

该研究在Berkeley镰状细胞病小鼠模型中,于约15%低氧暴露3个月诱导肺动脉高压后,使用口服铁转运蛋白抑制剂vamifeport治疗。结果观察到红细胞镰变减轻、血管内外溶血减少及心肺功能正常化,提示诱导轻度缺铁性贫血可能减轻镰状细胞病的心肺并发症。

要点

  • vamifeport可减轻Berkeley镰状细胞病小鼠的红细胞镰变和溶血。
  • vamifeport治疗使缺氧镰状细胞病小鼠的心肺功能正常化。
  • 诱导轻度缺铁性贫血可能成为减轻镰状细胞病心肺并发症的策略。

核心结论

  • vamifeport治疗可减轻缺氧Berkeley镰状细胞病小鼠的红细胞镰变、溶血及心肺功能障碍。

研究设计与样本

  • 研究使用Berkeley镰状细胞病小鼠,在约15%低氧暴露3个月诱导肺动脉高压表型后给予vamifeport治疗。

主要发现

  • Berkeley镰状细胞病小鼠在约15%低氧暴露3个月后表现为临床相关的肺动脉高压,平均肺动脉压25-35 mm Hg。
  • vamifeport治疗后观察到红细胞镰变减轻、血管外和血管内溶血减少以及心肺功能正常化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) is a genetically inherited hemoglobinopathy arising from homozygosity or compound heterozygosity for a single base pair mutation in hemoglobin β-globin gene (HBB), and the severity is affected by allelic combinations, haplotypes, and gene products. Numerous SCD mouse models exist to study mechanism and therapeutic intervention, and each display some phenotypic features of human disease. Berkeley SCD mice demonstrate clinically relevant pulmonary hypertension (mean pulmonary artery pressure, 25-35 mm Hg) when housed under subchronic (3-month) exposure to a moderately decreased oxygen level, ∼15%. This model accelerates red blood cell (RBC) sickling and hemolysis, which perpetuates precapillary pulmonary vascular disease and right ventricular dysfunction. Iron restriction in SCD is reported to attenuate the frequency and severity of vaso-occlusive crisis through reducing sickle hemoglobin in RBCs. Vamifeport is an oral clinical stage ferroportin inhibitor shown to improve microcirculatory blood flow in Townes-SS mice. We hypothesized that vamifeport treatment may attenuate right ventricular dysfunction and pulmonary vascular remodeling in Berkeley SCD mice that express a pulmonary hypertension phenotype. Further, we hypothesized that lung and right ventricle metabolism and protein expressions would show an antioxidant and iron-regulatory response that favors the attenuation of cardiopulmonary dysfunction. Indeed, attenuation of red cell sickling, reduced extravascular and intravascular hemolysis, and normalization of cardiopulmonary dysfunction was observed after vamifeport treatment. We suggest that induction of mild iron-deficiency anemia may attenuate deadly sequelae of SCD, including cardiopulmonary dysfunction.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lucero MJ, Setua S, Thangaraju K, et al. Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice. Blood Adv. 2026. PMID: 41538305. doi:10.1182/bloodadvances.2025018680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。